Last reviewed · How we verify
SHR2554; Chidamide analog tablets
Chidamide analog SHR2554 is an inhibitor of histone deacetylases (HDACs), which play a role in regulating gene expression.
Chidamide analog SHR2554 is an inhibitor of histone deacetylases (HDACs), which play a role in regulating gene expression. Used for Relapsed or refractory peripheral T-cell lymphoma.
At a glance
| Generic name | SHR2554; Chidamide analog tablets |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | HDAC inhibitor |
| Target | HDAC |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting HDACs, SHR2554 can modulate the acetylation status of histones and other proteins, leading to changes in gene expression that can affect cell growth, differentiation, and survival. This mechanism is thought to contribute to its therapeutic effects in various diseases.
Approved indications
- Relapsed or refractory peripheral T-cell lymphoma
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: